Gsa Capital Partners LLP Verona Pharma PLC Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Verona Pharma PLC stock. As of the latest transaction made, Gsa Capital Partners LLP holds 53,372 shares of VRNA stock, worth $3.39 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
53,372
Previous 29,513
80.84%
Holding current value
$3.39 Million
Previous $849,000
191.99%
% of portfolio
0.18%
Previous 0.06%
Shares
5 transactions
Others Institutions Holding VRNA
# of Institutions
219Shares Held
70.5MCall Options Held
1.4MPut Options Held
299K-
Perceptive Advisors LLC New York, NY6.39MShares$406 Million9.9% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$355 Million18.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$215 Million9.42% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.13MShares$199 Million2.79% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.13MShares$199 Million2.81% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $3.87B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...